The process of value building in science-based companies: Geron and the 'Telome-race'
by Anna S. Nilsson
International Journal of Biotechnology (IJBT), Vol. 7, No. 4, 2005

Abstract: Through the in-depth case of a biotechnology company, this paper contributes to an increased understanding of the strategic and organisational issues of pursuing scientific progress with commercial constraints and of how value is built in new science-based companies. A conclusion from this study is that the main mechanism enabling science-based companies to build value is the ability to adopt new scientific evidence and adjust the organisation accordingly. The identification and interaction with external actors emerges as key to this ability. Comparisons are made with other case studies, and the analysis provides support for the main argument of this paper: exploration, rather than exploitation, creates the base for value building in science-based companies.

Online publication date: Sun, 21-Aug-2005

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com